Skip to main content

Table 1 Patients’ characteristics at the baseline before and after matching

From: Neoadjuvant chemoradiotherapy improves survival in locally advanced adenocarcinoma of esophagogastric junction compared with neoadjuvant chemotherapy: a propensity score matching analysis

 

Before matching

After matching

nCRT (%)

nCT (%)

P

nCRT (%)

nCT (%)

P

All patients

81

89

 

60

60

 

Age

  

0.273

  

0.707

 ≥ 60

49 (60.5)

61 (68.5)

 

38 (63.3)

36 (60.0)

 

 < 60

32 (39.5)

28 (31.5)

 

22 (36.7)

24 (40.0)

 

Sex

  

0.062

  

0.509

 Male

75 (92.6)

74 (83.1)

 

56 (93.3)

54 (90.0)

 

 Female

6 (7.4)

15 (16.9)

 

4 (6.7)

6 (10.0)

 

Siewert type

  

0.000

  

0.456

 II

42 (51.9)

22 (24.7)

 

26 (43.3)

22 (36.7)

 

 III

39 (48.1)

67 (75.3)

 

34 (56.7)

38 (63.3)

 

ECOG

  

0.193

  

0.729

 0

9 (11.1)

5 (5.6)

 

4 (6.7)

5 (8.3)

 

 1

72 (88.9)

84 (94.4)

 

56 (93.3)

55 (91.7)

 

cT

  

0.030

  

0.822

 3

24 (29.6)

14 (15.7)

 

13 (21.7)

12 (20.0)

 

 4

57 (70.4)

75 (84.3)

 

47 (78.3)

48 (80.0)

 

cN

  

0.902

  

0.500

 N0

17 (21.0)

18 (20.2)

 

14 (23.3)

11 (18.3)

 

 N+

64 (79.0)

71 (79.8)

 

46 (76.7)

49 (81.7)

 

Her-2

  

0.258

  

0.395

 Unknown

35 (43.2)

47 (52.8)

 

26 (43.3)

25 (41.7)

 

 0/1

28 (34.6)

29 (32.6)

 

21 (35.0)

24 (40.0)

 

 2+

15 (18.5)

8 (9.0)

 

11 (18.3)

6 (10.0)

 

 3+

3 (3.7)

5 (5.6)

 

2 (3.3)

5 (8.3)

 
  1. cT clinical T stage, cN clinical N stage